Tiragolumab, a novel cancer immunotherapy discovered for the treatment of metastatic Non-small Cell Lung Cancer (NSCLC). Tiragolumab, is the first anti-TIGIT molecule introduced to bind with TIGIT, a protein receptor on immune cells. It functions as an immune amplifier, by improving the body’s immune response. By combining with TIGIT, tiragolumab blocks the interface with a poliovirus receptor (PVR, or CD155) a protein receptor which can suppress the body’s immune response.
TIGIT blocks the interaction with a protein called poliovirus receptor (PVR, or CD155) which can suppress the body’s immune response.
Tecentriq is a cancer immunotherapy which has the ability to bind with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. Tiragolumab combined with Tecentriq has shown efficacy and safety in PD-L1-positive metastatic NSCLC based on data from the phase II CITYSCAPE trial.
US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for anti-TIGIT tiragolumab in combination with Tecentriq® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC).
